CUSIP
No. 243733102
|
SCHEDULE 13G/A
|
Page 10
of 14 Pages
|
Item 1. | | (a) Name of Issuer |
Deep Medicine Acquisition Corp.
Item 1. | | (b) Address of Issuer’s Principal
Executive Offices |
595
Madison Avenue
12th
Floor, New York, New York 10017
Item 2. | | (a) Name of Person Filing: |
This
Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)
i)
Lighthouse Investment Partners, LLC (“Lighthouse”)
ii)
MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC (“MAP 136”)
iii)
MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC (“MAP 214”)
iv)
LHP Ireland Fund Management Limited (“LHP Ireland”)
v)
MAP 501, a sub-trust of LMA Ireland (“MAP 501”)
vi)
LMAP 909, a sub-fund of LMAP Ireland ICAV (“LMAP 909”)
vii)
LMAP 910, a sub-fund of LMAP Ireland ICAV (“LMAP 910”)
viii)
Shaolin Capital Partners SP, a segregated portfolio of PC MAP SPC (“Shaolin“)
This
Statement relates to the Issuer’s shares of common stock (“Shares”) directly beneficially owned by MAP 214, MAP
136, and Shaolin. Lighthouse serves as the investment manager of MAP 214, MAP 136, and Shaolin. LHP Ireland serves as the manager to
MAP 501, LMAP 909 and LMAP 910. Because Lighthouse and LHP Ireland may be deemed to control MAP 214, MAP 136, Shaolin, MAP 501, LMAP
909 and LMAP 910, as applicable, Lighthouse and LHP Ireland may be deemed to beneficially own, and to have the power to vote or direct the vote
of, and the power to direct the disposition of the Issuer’s Shares reported herein.
| | Address
of
Principal
Business Office: |